Details of the Drug Combinations

General Information of This Drug (ID: DMSFK9V)

• Drug Name: Daclatasvir (DMSFK9V)
• Synonyms: 1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410

Indication

Hepatitis C virus infection; ICD 11: 1E51.1; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

11 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BMS 650032 + Daclatasvir	DC4I062	BMS 650032	Hepatitis C Virus	[2]
BMS 650032 + Daclatasvir	DCENZT8	BMS 650032	Hepatitis C Virus Infection	[3]
Cobicistat + Daclatasvir	DCHZZAH	Cobicistat	Hepatitis C	[4]
Daclatasvir + INX-189	DCEMT7D	INX-189	Hepatitis C Virus	[5]
Daclatasvir + Atazanavir	DC0QK6O	Atazanavir	Hepatitis C	[4]
Darunavir + Daclatasvir	DCWAMCZ	Darunavir	Hepatitis C	[6]
Dolutegravir + Daclatasvir	DC6THDC	Dolutegravir	Infection, Human Immunodeficiency Virus	[7]
Simeprevir + Daclatasvir	DC8N7ND	Simeprevir	Hepatitis C Virus	[8]
Sofosbuvir + Daclatasvir	DC877J9	Sofosbuvir	Chronic Hepatitis C	[9]
Simeprevir + Daclatasvir	DCZ8I4I	Simeprevir	Renal Impairment	[10]
Sofosbuvir + Daclatasvir	DCDFXZP	Sofosbuvir	Hepatitis C	[11]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] ClinicalTrials.gov (NCT01581203) Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
• [3] ClinicalTrials.gov (NCT01428063) Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
• [4] ClinicalTrials.gov (NCT02565888) A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
• [5] ClinicalTrials.gov (NCT01629732) Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C
• [6] ClinicalTrials.gov (NCT02159352) Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
• [7] ClinicalTrials.gov (NCT02082808) Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects
• [8] ClinicalTrials.gov (NCT01628692) Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
• [9] ClinicalTrials.gov (NCT01359644) Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
• [10] ClinicalTrials.gov (NCT02397395) An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
• [11] ClinicalTrials.gov (NCT02032888) A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.